Abstract: Topical preparations containing a salt of a cholanic acid, a lipid, and optionally, one or more other pharmaceutically or cosmetically active substances, are disclosed. These preparations are used in pharmaceutical and/or cosmetic applications.

Abstract: The present invention relates to compositions including blends of microbial oils, methods of using such compositions, particularly as supplements for infant formula, and methods of increasing the amount of long chain polyunsaturated fatty acids in infant formula.

Abstract: A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## , pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.

Abstract: The invention relates to the use of p-chloro-N-(2-morpholinoethyl)benzamide in the treatment of anxiety disorders, such as, panic disorders, social phobia and obsessive compulsive disorder,

Abstract: Methods of using N,N'-disubstituted thiocarbamide compounds for reversibly inhibiting hyperthyroidism are provided. Active compounds reversibly inhibit catalytic iodination without producing sulfenic acid intermediates which can permanently inactivate thyroid peroxidase. By preventing sulfenic acid formation, side effects due to toxicity in liver and bone marrow can be reduced compared to currently used drugs. The compounds can be formulated for administration to a hyperthyroid patient until remission occurs with less risk of possible everdosing.

Abstract: The subject application discloses methods for modulating NMDA-mediated ion transport, and inhibiting non-NMDA glutamate-induced ion transport, in neuronal cells. The methods involve contacting a neuronal cell with an effective amount of the neurosteroid pregnenolone sulfate, or pharmacologically effective derivatives thereof.

Abstract: A combination of angiotensin-converting enzyme inhibitors and calcium antagonists for the treatment of proteinuria is disclosed. The invention relates to the prevention and therapy of proteinuria by administration of a combination of ACE inhibitor and calcium antagonist.

Abstract: Certain steroidal and non-steroidal compounds have been found to inhibit androgen and estrogen formation. Such inhibition may aid in the reduction of the activity of these hormones and may be useful in the treatment of diseases where, for example, inhibition of androgen or estrogen acitivity is desired. Preferred inhibitors also possess antiestrogenic activity, thus providing the advantage of a double inhibitory action both on estrogen formation and on estrogen action.

Abstract: The use of substituted 3,4-dihydro-2H-benzopyrans as remedies for obstructive functional disorders of the lungs and/or disorders of the efferent urinary passagesThe use of 3,4-dihydro-2H-benzo[b]pyrans of the formula I ##STR1## in which R.sup.1 represents H, OH, (C.sub.1 -C.sub.2)-alkoxy, (C.sub.1 -C.sub.2)-alkyl or NR.sup.4 R.sup.5, where R.sup.4 and R.sup.5 are identical or different and represent H, (C.sub.1 -C.sub.2)-alkyl or (C.sub.1 -C.sub.3)-alkyl-carbonyl,R.sup.2 and R.sup.3 are identical or different and represent alkyl having 1-4 carbon atoms,Ar represents an aromatic or heteroaromatic system which is unsubstituted or substituted by 1 to 3 identical or different radicals (C.sub.1 -C.sub.2)-alkyl, (C.sub.1 -C.sub.2)-alkoxy, halogen, trifluoromethyl, CN, NO.sub.2, CO--(C.sub.1 -C.sub.2)-alkyl or SO.sub.m --(C.sub.1 -C.sub.2)-alkyl with m=1 or 2,n represents 1 or 2,X represents a chain (CH.sub.2).sub.r which can be interrupted by a heteroatom O, S or NR.sup.6, where R.sup.6 denotes H or (C.sub.1 -C.

Abstract: Optically pure (S) metoprolol, which is substantially free of the (R) enantiomer, is a potent beta-blocker for treating myocardial infarction and for relieving the symptoms of angina pectoris, cardiac arrhythmia and hypertension in individuals. A method is disclosed utilizing the optically pure (S) configurational enantiomer of metoprolol for treating cardiovascular disorders while reducing undesirable side effects associated with the administration of beta-blockers.

Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging), Accordingly, a composition is disclosed which comprises 2-aminoimidazoles capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation, The method comprises contacting the target protein with the composition, Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Abstract: The applicant has identified a particular class of imidazoles that inhibit endothelial cell, vascular smooth muscle cell and fibroblast proliferation. These imidazoles can be used to beneficially treat a variety of arteriosclerotic conditions.

Abstract: A pharmaceutical dosage form comprising an HMG-CoA reductase inhibitor compound, e.g., fluvastatin sodium, is disclosed which is stabilized against pH-related degradation by an alkaline stabilizing medium capable of imparting a pH of at least 8 to an aqueous solution or dispersion of the composition.

Abstract: This invention provides novel vitamin D-related compounds characterized by extended unsaturated side chain structures. Such compounds exhibit increased activity in arresting the proliferation and promoting the differentiation of malignant cells with only minimal calcemic activity and thus represents new therapeutic agents applicable and uniquely useful in differentiation therapy of malignant diseases. The activity characteristics of these compounds provide the basis of a method for the treatment of neoplastic diseases, specifically leukemoid diseases.

Abstract: A method for the treatment of vaginal atrophy in a human patient in which retinoic acid is administered topically to the patient's vagina.

Abstract: A method of treatment of inflammatory diseases which comprises administering, to a subject in need of such treatment, an anti-inflammatorily effective amount of a 15-keto-prostaglandin compound.

Abstract: A particular group of androgens is not metabolized to their 5.alpha.-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6.alpha. or 7.alpha. position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7.alpha.-methyl-19-nortestosterone.

Abstract: A composition for the treatment of vaginal yeast which promotes normal vaginal bacterial growth during treatment, comprising a yeast-inhibitory agent selected from one or more of the group consisting of ethylene glycol, propylene glycol, and glycerol, and an effectively buffered aqueous acetate solution, in which the concentration of acetate is effective to establish a pH of the composition in the range of from about 5 to about 7, the presence of unionized acetate inhibits yeast selectively compared to the bacteria, and the proportions of the yeast-inhibitory agent and the buffering solution are effective to allow the active yeast-inhibitory agent to inhibit the vaginal yeast Candida. A method of treatment of vaginal yeast while promoting normal vaginal bacterial growth, by intravaginal application of the composition described above, is also disclosed.

Abstract: The present method for the treatment of pancreatitis, which comprises administering an effective amount of a pyrazolopyridine compound of the following formula: ##STR1## wherein R.sup.1 is lower alkyl, (substituted) aryl, or a heterocyclic group,R.sup.2 is a group of the formula ##STR2## wherein R.sup.4 is protected amino or hydroxy and R.sup.5 is hydrogen or lower alkyl; cyano; a group of the formula --A--R.sup.6, wherein R.sup.6 is an acyl group, and A is (halogenated) lower aliphatic hydrocarbon group; amidated carboxy; an unsaturated heterocyclic group; or (protected) amino; andR.sup.3 is hydrogen, lower alkyl, lower alkoxy or halogen; or a pharmaceutically acceptable salt thereof, to a human being having pancreatitis or an animal having pancreatitis in need thereof.

Abstract: An emulsified composition having an average particle size of 0.010 to 0.070 .mu.m contains at least the following components (A), (B) and (C):(A) a lipid-soluble drug and a lipid;(B) glycerol and water;(C) a phospholipid and/or a water-soluble nonionic surfactant having a molecular weight of 1000 or more, with (A)/(C) being 0.5 to 5 (weight ratio).